RNXT
RenovoRxFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Composite grade F from latest DB weights. Momentum 40.1 / Value 40.7
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-05 · AMC.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
40
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -Analysis date unavailable; returns require an exact persisted reference.
Earnings
2026-11-05 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.13
Why
Momentum40 · Δ7d -
Value41 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-05 · AMC.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Mixed signals. Wait for cleaner trend confirmation.
Catalyst clock
2026-11-05 · AMC
Lead driver: Value · See fundamentals
Momentum
40
15% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
85% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 40.1 / Value 40.7
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$67.24M
Beta
1.30
Shares Out
45.13M
P/E (TTM) · Derived
-4.7
P/S (TTM)
37.52
P/FCF (TTM) · Derived
-4.90
Rev YoY
+115.4%
EPS YoY
-22.2%
Gross Margin
+84.4%
Op Margin
-685.2%
Net Debt
-$6.81M
Current Ratio
5.74
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data